Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

Study Identifier
GLYX13-C201
CT.gov Identifier
NCT01234558
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Depression
    • Study Drug
  • GLYX-13
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * diagnosis of major depressive disorder consistent with DSM-IV-TR * current episode greater than 8 weeks in duration * Hamilton Depression score \>/- 21 * less than 25% reduction in depression during current episode assessed by ATRQ
    Exclusion Criteria:
    * Axis diagnosis of other psychiatric disorders * Experiencing hallucinations, delusions, other psychotic symptomatology * ECT during current episode

    Protocol Summary

    The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.

    Study Locations

    Location
    Status
    Location
    Mulitple
    Evanston, Illinois, United States, 60201
    Status
    Not applicable